熱門資訊> 正文
Biomea Fusion在临床搁置后在巴克莱银行裁员
2024-06-07 20:59
- Barclays has downgraded Biomea Fusion (NASDAQ:BMEA) to equal weight from overweight citing the June 6 announcement that the U.S. FDA placed a full clinical hold on phase 1/2 trials for BMF-219 for type 1 and type 2 diabetes.
- The firm also lowered its price target to $5 from $30 (~56% downside based on Thursday's close).
- Analyst Peter Lawson said the downgrade is being done until there is resolution on the hold, which was caused by potential drug-induced liver toxicity.
- Despite the setback, he expects initial expansion data from the type 3 trial, COVALENT-111, in the second half of the year as well as phase 2 data in from the open-label portion of the type 1 COVALENT-112 trial by the end of the year as well.
More on Biomea Fusion
- Biomea stock plunges 62% after hours on FDA clinical hold
- Biomea Fusion drops as JPMorgan downgrades on data for lead asset
- Seeking Alpha’s Quant Rating on Biomea Fusion
- Historical earnings data for Biomea Fusion
- Financial information for Biomea Fusion
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
